SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): July 6, 2022

COEPTIS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	**000-56194**	**84-3998117**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(I.R.S. Employer Identification No.)**
105 Bradford Rd, Suite 420 Wexford, Pennsylvania		**15090**
(Address of principal executive offices)		**(Zip Code)**

724-934-6467
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☒ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
N/A	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

On July 6, 2022, Coeptis Therapeutics, Inc. (the "Company" or "Coeptis") posted an investor presentation (the "Presentation") to its website and it is available in the Presentations section of the Company's website at https://coeptistx.com/presentation. A copy of the Presentation is included as Exhibit 99.1 to this Current Report on Form 8-K.

The Company intends to use the Presentation in presentations to investors and analysts from time to time in the future, including in connection with the proposed business combination involving the Company and Bull Horn Holdings Corp ("Bull Horn"). The furnishing of the information in this Current Report on Form 8-K is not intended to, and does not, constitute a determination by the Company that the information in this Current Report on Form 8-K is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company. The information in the materials is presented as of July 6, 2022, and the Company does not assume any obligation to update such information in the future.

The information in Item 7.01 of this Current Report on Form 8-K shall not be deemed to be "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Coeptis Therapeutics, Inc. Presentation

Additional Information and Where to Find It

This communication may be deemed to be solicitation material in respect of the proposed business combination with Coeptis and Bull Horn. Coeptis intends to file with the Securities and Exchange Commission (the "SEC") a preliminary proxy statement and a definitive proxy statement and other relevant materials in connection with the proposed business combination. The definitive proxy statement will be sent or given to the stockholders of Coeptis. This communication is not a substitute for the definitive proxy statement or any other document that may be filed by Coeptis with the SEC. SECURITY HOLDERS ARE ADVISED TO READ THE PROXY STATEMENT WHEN IT BECOMES AVAILABLE, BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS COMBINATION. The proxy statement and other relevant materials (when they become available), and any other documents filed by Coeptis with the SEC, may be obtained free of charge at the SEC's website, at www.sec.gov.

Participants in the Solicitation

Coeptis and its directors, executive officers, other members of management and employees may be deemed participants in the solicitation of proxies from Coeptis' stockholders with respect to the proposed business combination. Investors and securityholders may obtain more detailed information regarding the names and interests in the business combination of the directors and officers of Coeptis in Coeptis' filings with the SEC. Additional information regarding the interests of such potential participants will also be included in the preliminary proxy statement and definitive proxy statement when they are filed with the SEC.

No Offer or Solicitation

This Current Report on Form 8-K and the exhibits hereto do not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination. This Current Report on Form 8-K shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

Cautionary Note Regarding Forward-Looking Statements

Certain statements made herein and in the attached Presentation contain, and certain oral statements made by representatives of Coeptis and its respective affiliates, from time to time may contain, "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Bull Horn's and Coeptis' actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "might" and "continues," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, statements regarding (i) the technologies which are the subject of Coeptis' potential expansion focus, including its option agreement with the University of Pittsburgh, (ii) Coeptis' expectations with respect to future performance and anticipated financial impacts of the Bull Horn business combination, and (iii) the satisfaction of the closing conditions to such business combination and the timing of the completion of such business combination. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside of the control of Coeptis and are difficult to predict. Factors that may cause such differences include but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of that certain Agreement and Plan of Merger dated effective as of April 18, 2022 (as may be further amended or supplemented from time to time, the "Merger Agreement"), with Coeptis, Bull Horn and BH Merger Sub Inc. (a wholly-owned subsidiary of Bull Horn); (2) the inability to complete the business combination, including due to the failure to obtain approval of the shareholders of Bull Horn or other conditions to closing in the Merger Agreement; (3) the inability to obtain or maintain the listing of Bull Horn's securities on the Nasdaq Capital Market following the business combination; (4) the risk of significant redemptions by Bull Horn's public stockholders in connection with the closing of the business combination, leaving the combined post-closing company with limited funds to finance its business plans; (5) the risk that the business combination disrupts current plans and operations of Coeptis as a result of the announcement and consummation of the business combination; (6) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth economically and hire and retain key employees; (7) the risks that Coeptis' products in development (including those which may be acquired from the University of Pittsburgh) fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (8) costs related to the business combination and expansion opportunities, including in connection with any exercise of Coeptis' option with the University of Pittsburgh; (9) changes in applicable laws or regulations; (10) the possibility that Bull Horn or Coeptis may be adversely affected by other economic, business, and/or competitive factors; and (11) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties to be identified in the proxy statement (when available) relating to the business combination, including those under "Risk Factors" therein, and in other filings with the SEC made by Coeptis. The foregoing list of factors is not exclusive. Readers are referred to the most recent reports filed with the SEC by Coeptis. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Coeptis undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, subject to applicable law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Coeptis Therapeutics, Inc.

Date: July 6, 2022

By: /s/ David Mehalick
David Mehalick
Chief Executive Officer

Exhibit 99.1

Important Legal Disclaimers

This presentation (the "Presentation") has been prepared for informational purposes only to assist interested parties in evaluating an investment in connection with a proposed business combination (the "Business Combination") between Bull Horn Holdings Corp. ("Bull Horn") and Coeptis Therapeutics, Inc. ("Coeptis"). The closing of the Business Combination will be subject to satisfaction of the closing condition set forth therein. In connection with the closing of the Business Combination, Bull Horn will re-domesticate as a Delaware corporation and will change its name. The continuing combined entity is hereinafter referred to as the "Company".

No Offer or Solicitation: This Presentation is for informational purposes and does not constitute a "solicitation" pursuant to Section 14 of the Securities Exchange Act of 1934, as amended or the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") promulgated pursuant thereto. This Presentation does not constitute (i) a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the Business Combination or (ii) an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security of Bull Horn, Coeptis, or any of their respective affiliates nor shall there be any sale of securities, investment or other specific product in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF ANY OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

Important Legal Disclaimers cont'd.

Participants in Solicitation: Bull Horn and Coeptis and their respective directors and executive officers may, under SEC rules, be deemed to be participants in the solicitation of proxies or consents of Bull Horn's or Coeptis' respective shareholders in connection with the Business Combination. Investors and security holders may obtain more detailed information regarding the names and interests in the Business Combination of Bull Horn's and Coeptis' respective directors and officers in Bull Horn's and Coeptis' filings with the SEC, including Bull Horn's and Coeptis' respective Annual Reports on Form 10-K for the fiscal year ended December 31, 2021. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to Bull Horn's or Coeptis' shareholders in connection with the Business Combination will be set forth in the proxy statement/prospectus included in the registration statement on Form S-4 with respect to the Business Combination, which has been to be filed by Bull Horn with the SEC.

Additional Information and Proxy Statement: In connection with the proposed Business Combination, Bull Horn has filed with the SEC a Registration Statement on Form S-4, containing a preliminary proxy statement/prospectus of Bull Horn and Coeptis and after the registration statement is declared effective, Bull Horn and Coeptis will mail a definitive proxy statement/prospectus relating to the proposed Business Combination to their respective shareholders.

Important Legal Disclaimers cont'd.

This Presentation does not contain any information that should be considered by Bull Horn's or Coeptis' respective shareholders concerning the proposed Business Combination and is not intended to constitute the basis of any voting or investment decision in respect of the Business Combination or the securities of Bull Horn or Coeptis. Interested persons are advised to read the preliminary proxy statement/prospectus and the amendments thereto and the definitive proxy statement/prospectus and other documents filed in connection with the proposed Business Combination, as these materials will contain important information about Bull Horn, Coeptis and the Business Combination. When available, the definitive proxy statement/prospectus and other relevant materials relating to the proposed Business Combination will be mailed to shareholders of Bull Horn and Coeptis as of a record date to be established for voting on the proposed Business Combination.

The information contained in the Presentation does not purport to be all-inclusive or to contain all information that may be required to make a full analysis of an investment in Bull Horn, Coeptis or the Business Combination, and you should conduct your own independent evaluation and due diligence with respect to Bull Horn, Coeptis and the terms of the Business Combination. The general explanations included in this Presentation are not intended to, and cannot, address your specific investment objectives, financial situations or financial needs. You should consult with you own legal counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, and, by accepting this Presentation, you confirm that you are not relying solely upon the information contained herein to make any investment decision.

Important Legal Disclaimers cont'd.

No Representation: Neither Bull Horn nor Coeptis, nor any of their respective subsidiaries, shareholders, affiliates, representatives, control persons, partners, members, managers, directors, officers, employees, advisers or agents make any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation. To the fullest extent permitted by law, in no circumstances will Bull Horn, Coeptis or any of their respective subsidiaries, shareholders, affiliates, representatives, control persons, partners, members, managers, directors, officers, employees, advisers or agents be responsible or liable for any direct, indirect or consequential loss or loss of profit arising from the use of this Presentation, its contents, its omissions, reliance on the information contained within it, or on opinions communicated in relation thereto or otherwise arising in connection therewith.

Date of Information: This Presentation speaks only as of the date hereof. Neither Bull Horn nor Coeptis intend to update or otherwise revise this Presentation following its distribution, except the extent required by law. Neither Bull Horn nor Coeptis makes any representation or warranty, express or implied, as to the accuracy of completeness of any of the information contained in this Presentation.

This Presentation is not a substitute for the proxy statement/prospectus or for any other document that Bull Horn or Coeptis may file with the SEC in connection with the Business Combination. INVESTORS AND SECURITYHOLDERS ARE ADVISED TO READ THE DOCUMENTS FILED WITH THE SEC CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and shareholders may obtain free copies of other documents filed with the SEC by Bull Horn or Coeptis through the website maintained by the SEC at www.sec.gov.

Important Legal Disclaimers cont'd.

Risk Factors

The below list of risk factors has been prepared as part of the Business Combination. The risks presented below are a subset of the general risks related to the business of Coeptis and the proposed Business Combination. and such list is not exhaustive. The list below has been prepared solely for purposes of this presentation and not for any other purpose. The list below is qualified in its entirety by disclosures contained in documents previously or hereafter filed or furnished by Bull Horn or Coeptis with the SEC, and you should carefully consider these risks and uncertainties, together with the financial statements and related notes filed with the SEC. If Coeptis cannot address any of the following risks and uncertainties effectively, or any other risks and difficulties that may arise in the future, its business. financial condition and results of operations could be materially and adversely affected. The risks described below are not the only risks that Coeptis or Bull Horn faces. Additional risks that are currently not known about or that are currently believed to be immaterial may also impair its business, financial condition or results of operations. You should review this presentation and perform your own due diligence and consult with your own financial and legal advisors prior to making any decision in respect of Bull Horn, Coeptis or the Company. Risks relating to the business of Coeptis and Bull Horn will be disclosed in future documents filed or furnished by Coeptis and/or Bull Horn with the SEC, including the documents filed or furnished in connection with the proposed Business Combination. The risks presented in such filings will be consistent with those that would be required for a public company in its SEC filings, including with respect to the business and securities of Coeptis and Bull Horn and the proposed Business Combination, and may differ significantly from, and be more extensive than, the following risks presented below.

- The consummation of the Business Combination is subject to a number of conditions, and if any of those conditions are not satisfied or waived, Business Combination may not be completed;

Important Legal Disclaimers cont'd.

Risk Factors

- If the Business Combination is consummated, there is no assurance that we will achieve the intended benefits of the Business Combination;
- Adverse impacts from the pandemic involving the novel coronavirus known as COVID-19;
- The impact of damage to or interruption of our information technology systems due to cyber-attacks or other circumstances beyond our control;
- Business interruptions resulting from geographical actions, including war and terrorism;
- We may not be able to successfully implement our growth strategy on a timely basis or at all;
- We may have difficulties managing our anticipated growth, or we may not grow at all;
- We have a history of losses, we expect to incur losses in the future and we may not be able to achieve or maintain profitability;
- We may not be able to initiate and complete preclinical studies and clinical trials for our product candidates which could adversely affect our business;
- We may not be able to obtain and maintain the third-party relationships that are necessary to develop, commercialize and manufacture some or all of our product candidates;
- We may encounter difficulties in managing our growth, which could adversely affect our operations;
- We need to obtain financing in order to continue our operations, which may not be available on attractive terms or at all;
- We may, for financing or other reasons, have to delay, scale back or discontinue some of our product candidate development programs or future commercialization efforts;
- There are no assurances that any of the opportunities described in this presentation (including VyGen-Bio, Inc.'s assets, the CAR-T technologies and the agonist platform), each of which is early-stage, pre-clinical or clinical, will result in a commercial product or overcome the risks associated with early-stage biotech drug development;

Important Legal Disclaimers cont'd.

Risk Factors

- The drug development and approval process is uncertain, time-consuming and expensive;
- Competition in the biotechnology and pharmaceutical industries may result in competing products, superior marketing of other products and lower revenues or profits for us;
- Federal laws or regulations on drug importation could make lower cost versions of our future products available, which could adversely affect our revenues, if any;
- The regulatory approval process is costly and lengthy, and we may not be able to successfully obtain all required regulatory approvals;
- Healthcare reform measures could adversely affect our business;
- Protecting and defending against intellectual property claims may have a material adverse effect on our business;
- Certain of our estimates of market opportunity and forecasts of market growth could prove to be inaccurate;
- Potential legal proceedings in connection with the Business Combination, the outcome of which may be uncertain, could delay or prevent the completion of the Business Combination;
- If we are not able to retain our current senior management team and our scientific advisors or continue to attract and retain qualified scientific, technical and business personnel, our business will suffer; and
- There is a substantial doubt about our ability to continue as a going concern.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this Presentation, and statements by management or other persons acting by or on behalf of Bull Horn or Coeptis made in connection with this Presentation, constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to significant known and unknown risks, uncertainties and other factors that are difficult to predict and are beyond the control of both Bull Horn and Coeptis. The actual results, level of activity, performance or achievements of Bull Horn or Coeptis may be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forwards-looking statements.

Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "future," "outlook," and similar expressions that predict or indicate future events or trends. All statements that are not statements of historical matters are forward-looking statements. The forward-looking statements include, but are not limited to, statements concerning the expected terms and timing of the Business Combination and any financing undertaken in connection with the Business Combination.

The forward-looking statements made in this Presentation are based on Coeptis' current assumptions and judgments regarding future events and results. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Bull Horn and Coeptis. Some important factors that could cause actual results to differ materially from those in any forward-looking statements could include changes in domestic and foreign business, market, financial, political and legal conditions. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied upon as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability.

COEPTIS THERAPEUTICS

We are a Pittsburgh, PA based pharmaceutical company founded by an experienced team developing **innovative cell therapy platforms in oncology**.

Corporate Highlights

MERGER AGREEMENT WITH BULL HORN HOLDINGS

Announced entry into definitive merger agreement with Bull Horn Holdings Corp. (Nasdaq: BHSE), a special purpose acquisition company (SPAC).

Transaction expected to provide opportunity to enhance Coeptis' ability to progress its innovative cell therapy platforms for cancer and TLR5 agonist clinical pipeline.

CD38+ CANCERS – INITIAL GEAR-NK TARGET

VyGen-Bio's GEAR-NK enables development of modified NK cell-based therapeutics optimized to be co-administered with targeted antibodies.

CD38-GEAR-NK are modified NK cells that can avoid being ablated by therapies designed to target the CD38 antigen.

OPTION FOR CAR-T PLATFORM WITH MULTIPLE APPLICATIONS

Exclusive option agreement with University of Pittsburgh provides access to three potentially groundbreaking CAR-T technologies.

CAR-T platform early-indications offer potential to target hematologic and solid tumors, including breast and ovarian cancer.

OPTION FOR ENTOLIMOD – CLINICAL STAGE, TLR5 AGONIST

Right to acquire toll-like receptor 5 (TLR5) agonist platform, including entolimod.

Entolimod is a clinical-stage product currently being developed as a treatment for acute radiation syndrome.

Coeptis Merger Agreement – Bull Horn Holdings

MERGER AGREEMENT

Coeptis entered into definitive merger agreement for a business combination that will result in Coeptis becoming a wholly-owned subsidiary of Bull Horn Holdings Corp. (Nasdaq: BHSE), a special purpose acquisition company (SPAC).

KEY TRANSACTION TERMS

Under the terms of the merger agreement, a wholly-owned subsidiary of Bull Horn will merge with and into Coeptis.

At the close of the transaction, Bull Horn will be rebranded with "Coeptis" in its name and expects to be listed on Nasdaq under the ticker symbol "COEP."

Bull Horn to re-domesticate to Delaware.

GO-FORWARD PLAN

Merger provides Coeptis access to capital needed to advance product portfolio highlighted by CD38-GEAR-NK and CD38-Diagnostic; license/acquire Pitt and TLR5 agonist assets.

David Mehalick to lead combined company as President and CEO. Chris Calise, CFO of Bull Horn, to join the combined company Board.

Multiple Growth Drivers – Pre/Post Merger



Business Combination values Coeptis at $175 million (subject to adjustments).

Business Combination value agreed to prior to TRL5 agonist and Pitt agreements, suggesting near-term and longer-range upside potential.

Coeptis Collaboration – VyGen-Bio

EXCLUSIVE OPTION AGREEMENT

Coeptis entered into two exclusive option agreements with VyGen-Bio, Inc., a majority-owned subsidiary of Vycellix, Inc., involving technologies designed to improve the treatment of CD38-related cancers.

DEVELOP & COMMERCIALIZE

Coeptis will assist VyGen-Bio in its efforts to develop and commercialize:

- **CD38-GEAR-NK**, is a pre-clinical *in vitro* proof of concept product designed to protect CD38+ NK cells from destruction by anti-CD38 mAbs.
- **CD38-Diagnostic**, a discovery-stage product designed to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.

PARTNERSHIP STATUS

Coeptis currently has a 50% (which could scale down to 25%) revenue stream interest and co-development rights for CD38-GEAR-NK and a 50% revenue stream interest related to CD38-Diagnostic from VyGen-Bio. Coeptis is entitled to receive future revenue from both products.

GEAR-NK (CD38) STRATEGY

Natural Killer (NK)
Immune Effector Cell

Animations herein are provided as visual aids to help articulate hypothesized proof-of-concept in a general manner and do not depict precise scientific mechanisms-of-action.

IMMUNOTHERAPY CHALLENGES

Various immunotherapies for CD38+ tumors are designed to find and kill cells that express the CD38 antigen; therefore, CD38+ NK cells are likely to become collateral damage and with their eradication, the overall anti-tumor response is suboptimal.

THE GOAL

To protect CD38+ Natural Killer (NK) cells so that functional disease-targeting NK cells will not be eradicated, enabling their co-existence with CD38 targeting therapies, and thus allowing for complementary tumor killing and immune surveillance.

A NOVEL COMBINATORIAL APPROACH

Modified NK cells that are co-administered with select monoclonal antibodies and/or other CD38 targeting immunotherapies are in pre-clinical development to enhance and maximize tumor kill via combinatorial approaches otherwise not possible.

CURRENT ANTI-CD38 PATHWAY

Anti-CD38 mAbs (Infused antibodies from current cancer treatments) bind to CD38 proteins and kill both CD38+ Cancer cells and our body's Natural Killer Cells.



PATHWAY WITH GEAR-NK (CD38) CELL THERAPY

CD38-GEAR-NK are modified, NK cells that can avoid being ablated by therapies designed to target the CD38 antigen, thus enabling the combination of passive immunity with innate active immunity to more efficiently target and eradicate CD38+ malignancies.



Animations herein are provided as visual aids to help articulate hypothesized proof-of-concept in a general manner and do not depict precise scientific mechanisms-of-action.

CD38-GEAR-NK – Market Opportunity

CD38-GEAR-NK could change how CD38-related cancers are treated by protecting CD38+ NK cells from destruction by anti-CD38 mAbs.

- Opportunity to improve the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia

Multiple myeloma is expected to be the first cancer indication targeted with CD38-GEAR-NK.

The multiple myeloma market in the initial 8 target markets[1] was $16.27B in 2019 and is expected to increase through 2030.[2]

[1] US, UK, Germany, Spain, France, Italy, China, and Japan
[2] Source: DelveInsight

CD38-Diagnostic – Product Overview

1. CD38-Diagnostic is an ***in vitro screening tool*** to be used prior to initiation of mAb therapy.

2. Being developed to pre-determine which **cancer patients are most likely to benefit from targeted anti-CD38 mAb therapies**, either as monotherapy or in combination with CD38-GEAR-NK.

3. **Potential to develop as platform technology beyond CD38** to identify patients likely to benefit for a broad range of mAb therapies **across multiple indications**.

CD38-Diagnostic – Market Opportunity

CD38-Diagnostic provides opportunity to make more cost-effective medical decisions for the treatment of B cell malignancies with high CD38 expression including multiple myeloma.

- May help to avoid unnecessary administration of anti-CD38 therapies

Could prevent patients from being subjected to ineffective therapy and enable significant savings to healthcare systems

CD38-Diagnostic designed to be offered as a companion diagnostic for determining patient suitability and likelihood of positive treatment outcomes for CD38-GEAR-NK and/or CD38 monoclonal antibody therapies.

CD38-Diagnostic – Value Proposition

FLEXIBILITY

Designed to be used as a companion with CD38 GEAR-NK or as a standalone diagnostic screening test to determine which immunotherapies may be responsive to CD38+ tumors

Opportunity to expand the market to include use with other monoclonal antibody treatments for additional types of cancers

SPEED TO MARKET

As a medical device, the pathway to FDA approval is often shorter, thereby reducing development costs and increasing speed to market

RETURN ON INVESTMENT

Screening and identifying ineffective monoclonal antibody therapies would enable health insurance plans to approve and reimburse the diagnostic

GEAR PLATFORM ADVANTAGES

1. Each GEAR platform being designed to be deployed independently or collectively to further **bolster the likelihood of a durable therapeutic response**.

2. GEAR Diagnostic being designed to determine the most appropriate anti-CD38 mAb.

   GEAR NK being designed to help to protect the body's NK cells from being eradicated during mAb therapy.

3. When deployed collectively, GEAR NK and GEAR DIAG may enable a **more robust treatment option** when compared to existing regimens for the treatment of CD38+ cancers.

Coeptis Option – University of Pittsburgh

EXCLUSIVE OPTION AGREEMENT

Coeptis entered into an exclusive option agreement with the University of Pittsburgh for the rights to negotiate licenses to three CAR-T technologies that offer the potential to address a range of hematologic and solid tumors.

DEVELOP & ADVANCE

Exclusive option agreement involves the intellectual property rights to three technologies:

- **mSA2 affinity-enhanced biotin-binding CAR**
- **Universal self-labeling SynNotch and CARs for programable antigen-targeting**
- **Conditional control of universal CAR-T cells through stimulus-reactive adaptors**

PARTNERSHIP STATUS

Coeptis has until October 29, 2022, to exercise the option. The option agreement may be extended an additional six months, subject to the agreement of both parties.

CAR-T Platform – Market Opportunities

CAR-T offers the potential to revolutionize cancer treatment; however, there remain shortcomings with current CAR-T therapies that could enable the technology to be utilized with additional types of cancer, including many solid tumors.

- Among the initial cancer indications under development are pre-clinical programs targeting **breast cancer** and **ovarian cancer**

CAR-T cell therapy market size & share expected to reach $20.56 billion by 2029 from $1.96 billion in 2021, at a compound annual growth rate (CAGR) of 31.6% during forecast period 2022 to 2029.[1]

[1]Source: Polaris Market Research

CAR-T Platform – Core Opportunities

1. Creating a **universal CAR-T system** that maintains a **high-binding affinity**, while also offering **greater control over toxicity**.

2. Developing a technology that can **target multiple antigens simultaneously**.

3. Enabling conditional cell receptor control for **systemic control over CAR-T cells**.

Coeptis Strategic Agreement – TLR5 Agonist Platform

STRATEGIC AGREEMENT

Coeptis entered into a strategic agreement giving it the right to acquire toll-like receptor 5 (TLR5) agonist platform, including entolimod, a clinical-stage product currently being developed as a treatment for acute radiation syndrome. Coeptis is currently conducting its due diligence to explore this opportunity.

DEVELOP & ADVANCE

Potential addition of TLR5 agonist platform, led by entolimod, a clinical-stage candidate, could significantly enhance Coeptis' development pipeline.

AGREEMENT TERMS

If consummated, Coeptis would pay $6,000,000 (funded with a debt facility) and revenue-based milestone payments to be defined in the definitive agreement in exchange for a defined set of purchased assets that include rights to any product containing entolimod as an active ingredient and all other related TLR5 agonists

TLR5 Agonist – Treatment Opportunities

TLR5 is an innate immunity receptor, which when activated, triggers nuclear factor kappa B (NF-kB) signaling, mobilizing an innate immune response that drives expression of numerous genes.

- Entolimod is currently in development to treat **acute radiation syndrome**. Entolimod has also demonstrated preclinical potential in hematology, specifically the treatment of **neutropenia** and **anemia** in cancer patients.

Rising incidence of radiation toxicity in healthcare and chemical industries should create the potential to push continued demand for effective treatment.

The global radiation toxicity treatment market is estimated at $3.76B in 2022 and is expected to reach $5.9B by 2029.[1]

[1]Source: Future Market Insights

Coeptis Scientific Advisory Board

Evren Alici M.D., Ph.D.

Head of the Gene and Cell Therapy Group, Division of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm

Hans-Gustaf Ljunggren, M.D., Ph.D.

Former Dean of Research, Karolinska Institutet and founder of the Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm

Arnika K. Wagner, Ph.D.

Assistant Professor, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm

COEPTIS MANAGEMENT TEAM

Dave Mehalick
Co-Founder,
President & CEO

30 years of diverse business experience in healthcare, information technology and finance including consulting, capital markets, private equity, and investments

Christine Sheehy
Co-Founder & CFO

30 years of finance and operational experience, mainly in pharmaceutical and life science startup companies leading design and development of global systems

Gary Conte
SVP Sales and Marketing

30 years of pharmaceutical experience including senior roles in sales, marketing, business development, training, managed care, analytics and reporting

Dan Yerace
Co-Founder &
VP Operations

10+ years of pharmaceutical experience including roles in global supply chain, operations, business development, and procurement

Anticipated Milestones

Q2
- Expand IP portfolio around GEAR-NK and GEAR Diagnostic
- Expand ownership of VyGen-Bio and entire GEAR Platform

Q3
- Complete merger agreement with Bull Horn Holdings
- COEP stock to begin trading on Nasdaq following Bull Horn merger
- Complete due diligence of TLR5 agonist platform and determine and execute on next steps

Q4
- Finalize licensing agreement with University of Pittsburgh for CAR-T platform

Q1'23
- Initiate IND enabling studies for GEAR-NK (Toxicology, Pharmacology, PK)

Coeptis Value Proposition

- Cell and gene therapies have the potential to "disrupt" current treatment paradigms.
- Early-stage development assets in this space are being routinely acquired by larger Pharma companies.
- Entolimod, if acquired, would add clinical-stage asset to development pipeline targeting a condition – acute radiation syndrome – of increasing need due to geopolitical climate.
- Merger with Bull Horn will advance COEP stock to Nasdaq and provide opportunity to strengthen access to capital.

Coeptis Investor Relations Contact:

Bill Borden
Senior Vice President
Tiberend Strategic Advisors
Mobile: 732-910-1620
bborden@tiberend.com
coeptistx.com

